Welcome to our dedicated page for Lisata Therapeutics SEC filings (Ticker: LSTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lisata Therapeutics, Inc. filings document material events, operating updates, and capital-structure matters for a clinical-stage pharmaceutical company focused on certepetide and related solid-tumor therapy development. Recent Form 8-K disclosures include financial results, Regulation FD materials, corporate presentations, material agreements, shareholder-voting matters, governance topics, and clinical or regulatory disclosures.
The filing record also documents changes to certepetide commercialization rights, including the termination of a Greater China license and collaboration agreement related to research, development, and commercialization of the product candidate. These disclosures frame Lisata’s formal reporting around program development, partnership economics, public-company governance, and transaction-related capital structure matters.
Lisata Therapeutics amended its merger agreement with Kuva Labs to adjust the planned tender offer for Lisata’s common stock. The amendment moves the offer commencement deadline to June 10, 2026 and extends the transaction “Outside Date” from July 1, 2026 to July 17, 2026, with a further extension to August 17, 2026 available if Kuva Labs pays a non‑refundable $1.5 million fee.
Lisata agreed to certain covenants not to sue and waivers of claims related to Kuva’s delayed offer launch and missed $250,000 interim operating payment, in exchange for staged payments of $150,000 on June 12, 2026 and $100,000 on June 26, 2026. These protections fall away if Kuva fails to make required payments or materially breaches the amendment. Kuva’s acquisition vehicle acknowledged that it does not yet have committed financing and agreed this is material information for Lisata stockholders that will be disclosed and updated in its tender offer filings.
Lisata Therapeutics disclosed preliminary communications regarding a planned tender offer by Kuva Acquisition Corp., a direct wholly owned subsidiary of Kuva Labs Inc., pursuant to an Agreement and Plan of Merger dated March 6, 2026. The communication states the tender offer has not yet commenced and that formal Schedule TO and Schedule 14D-9 materials will be filed if and when the offer is launched. Stockholders are directed to review the tender offer materials and the solicitation/recommendation statement when filed, and are told those materials will be made available free of charge on Lisata’s investor site and the SEC website.
Lisata Therapeutics, Inc. reports that Kuva Labs’ subsidiary, which agreed to launch a tender offer to acquire all Lisata common stock, did not commence the offer on June 1, 2026 as expected under the amended merger agreement. Parent is negotiating with potential financing sources and is reevaluating the timing of the tender offer, and there is no assurance that the offer will commence. The company highlights that, if the tender offer begins, investors will receive detailed tender offer materials and a related Lisata recommendation statement to help them decide whether to tender their shares.
Lisata Therapeutics disclosed preliminary communications about a planned tender offer and merger agreement with Kuva Acquisition Corp., a wholly owned subsidiary of Kuva Labs Inc. The parties reference an Agreement and Plan of Merger, dated March 6, 2026, and state the tender offer has not commenced. The communication is for informational purposes only and is not an offer or solicitation.
The filing says that, if the tender offer is commenced, Parent and Purchaser will file a Schedule TO and Lisata will file a Schedule 14D-9. The document includes a cautionary note on forward-looking statements and identifies an Exhibit 99.1 press release dated May 29, 2026.
Lisata Therapeutics, Inc. amended its merger agreement with Kuva Labs, changing the tender offer consideration structure for its common stock. The upfront cash component per share is reduced from $5.00 to $4.00, while the contingent value right now allows for up to $3.00 in milestone-based cash payments.
Each CVR can pay $1.25 upon a defined Phase 2a GBM trial milestone and $1.75 upon regulatory filing or acceptance of a marketing application for certepetide. The parties also extended the tender offer commencement deadline to June 1, 2026 and pushed the merger "Outside Date" to July 6, 2026.
Lisata Therapeutics reported a net loss of about $4.5 million for the quarter ended March 31 2026, slightly improved from the prior year period. Operating expenses fell to $4.9 million as research and development dropped 53.7% to $1.2 million after winding down the BOLSTER trial and cutting clinical staff.
General and administrative costs rose 15.2% to $3.7 million, mainly from legal and consulting fees related to a proposed acquisition by Kuva Labs. Lisata ended the quarter with $13.1 million in cash and cash equivalents and working capital of about $10.7 million, but management concluded there is substantial doubt about the company’s ability to continue as a going concern without new funding.
Lisata terminated its Qilu license for certepetide in Greater China, eliminating up to $200 million in potential milestones and future royalties from that deal. Under a signed merger agreement, Kuva plans a tender offer at $5.00 per share plus a $1.00 contingent value right tied to future regulatory success for certepetide, though the offer has been delayed and may not be completed.
Kuva Acquisition Corp. (through a direct wholly owned subsidiary) disclosed preliminary communications regarding a planned tender offer to acquire Lisata Therapeutics, Inc. under an Agreement and Plan of Merger dated March 6, 2026. The communication states the tender offer has not yet commenced and that formal Schedule TO and Schedule 14D-9 materials will be filed if and when the offer is launched.
The filing cautions that the transaction remains subject to closing conditions, potential competing offers, regulatory and litigation risks, and that milestone consideration tied to a CVR may never be achieved.
Lisata Therapeutics, Inc. entered into an amendment and waiver with Kuva Labs Inc. and Kuva Acquisition Corp. to modify their existing Merger Agreement. The change extends the deadline for Kuva’s subsidiary to commence its tender offer for all outstanding Lisata common shares from April 13, 2026 to May 29, 2026, or another mutually agreed date.
Under the amendment, Kuva Labs agrees to pay certain Lisata expenses up to $1.1 million in total until the tender offer begins. In return, Lisata agrees not to pursue specified claims related to the Merger Agreement until May 29, 2026, and to waive certain claims tied to the earlier missed tender-offer start date once the offer begins and agreed payments are made, subject to termination rights if Kuva defaults or materially breaches the amendment.
Lisata Therapeutics, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, executive compensation, ownership and governance that was omitted from the original filing. The company reports an aggregate market value of common stock held by non‑affiliates of about $23.6 million as of June 30, 2025, based on a Nasdaq price of $2.90 per share, and 9,106,391 shares outstanding as of April 28, 2026. The six‑member board is classified, with a majority deemed independent, and operates audit, compensation, nominating/governance, and science and technology committees. The filing discloses 2025 compensation for key executives, including total compensation of about $1.15 million for CEO David J. Mazzo, primarily salary and equity with no annual bonus, and describes severance and change‑in‑control protections. A forward‑looking statement section highlights risks such as a proposed acquisition by Kuva Labs, Inc., capital needs, ability to continue as a going concern, clinical trial execution and regulatory dependence.
Lisata Therapeutics, Inc. reports that Kuva Labs Inc. has not yet commenced the planned tender offer to acquire all outstanding Lisata common shares under their March 6, 2026 Merger Agreement. The deadline for Kuva’s acquisition subsidiary to begin the offer was previously extended to April 13, 2026.
Lisata states that Kuva is seeking alternative, more favorable financing to fund the tender offer and intends to launch the offer once that financing is finalized. Lisata and Kuva are in discussions about the financing and timing, but there is no assurance the tender offer will commence or the transaction will close.